Combined treatment with intravenous prostacyclin and sildenafil in patients with pulmonary hypertension: Report of 4 cases;Tratamiento combinado con prostaciclina intravenosa y sildenafilo en pacientes con hipertensión arterial pulmonar: Descripción de 4 casos

Medicina Clinica

Volumn 122, Issue 2, 2004, Pages 64-66

  García Hernández, Francisco José ^a   Ocaña Medina, Celia ^a   Mateos Romero, Luis ^a   Martínez Martínez, Ángel ^a   Bautista Lorite, Andrés ^a   Santos Ramos, Bernardo ^a   Sánchez Román, Julio ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b NONE   (Spain)

Author keywords

Prostacyclin; Pulmonary hypertension; Sildenafil

Indexed keywords

COLLAGEN; PROSTACYCLIN; SILDENAFIL;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; COLLAGEN DISEASE; COMBINATION CHEMOTHERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG POTENTIATION; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HUMAN; LUNG ARTERY PRESSURE; PULMONARY HYPERTENSION; TREATMENT FAILURE; WALKING;

EID: 1142298948     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(04)74143-3     Document Type: Article

References (21)

1. Rubin U. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
2. Barberá JA. Hipertensión pulmonar: criterios actuales de diagnóstico y tratamiento. Med Clin (Barc) 2002;118:590-6.
3. Rich S, editor. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998; 1998, September 6-10; Evian, France. Co-sponsored by The World Health Organization. Disponible en: http://www.who.it/ ncd/cvd/pph.html
4. Sáenz de la Calzada C, Sánchez Sánchez V, Velázquez Martín MT, Tello de Meneses R, Gómez Sánchez MA, Delgado Jiménez J, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en tromboembolismo e hipertensión pulmonar. Rev Esp Cardiol 2001;54:194-210.
5. Barst RJ, Rubin U, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
6. McLaughlin W, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
7. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000;132:435-43.
8. Schenk P, Petkov V, Madl C, Kramer L, Kneussl M, Ziesche R, et al. Aerosolized iloprost therapy could not replace long-term iv epoprostenol (prostacyclin) administration in severe pulmonary hypertension. Chest 2001;119:296-300.
9. Machherndl S, Kneussl M, Baumgartner H, Schneider B, Petkov V, Schenk P, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 2001;17:8-13.
10. Galie N, Manes A, Branzi A, Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001;22:529-37.
11. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:800-4.
12. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
13. Rubin U, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al, for the Bosentan Randomized Trial of Endothelin Antagonist Therapy Study Group. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
14. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342.
15. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22.
16. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000;84:E4.
17. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-22.
18. Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002;71:398-402.
19. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-403.
20. Wheeler W, Hayes S, Nguyen N, Cilla AM, Rybowicz J, Jones CC, et al. Sildenafil - a possible treatment for acute pulmonary hypertension during cardiac surgery. BUMC proceedings 2002;15:13-5.
21. Stiebellehner L, Petkov V, Vombank K, Funk G, Schenk P, Ziesche R, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293-5.